(2 years, 10 months ago)
Commons ChamberWhere I agree with the right hon. Gentleman is on the importance of persuasion in vaccination. Where I am afraid I disagree with him is on the idea that public ownership of patents connected with vaccinations or drug development in general would help. In fact, I think it would be a backward step and we would not see the innovation that has saved lives.
Many patients in hospital will presumably be protected by having undertaken their own vaccination process, but some will be clinically extremely vulnerable because of compromised immune systems. Is the Secretary of State saying that these people are at no greater risk of being made seriously ill or dying as a result of coming into contact with unvaccinated frontline staff? If they are at greater risk, is there something else that can be done to lessen that risk, such as a testing regime, before that contact takes place?
That is another good question from my right hon. Friend. I will say two things. First, this is not about zero risk; it is about less risk. What I am saying is that, based on the advice that I have received and for the reasons that I set out in my statement, whether or not someone is immunosuppressed, omicron, in general, represents less risk. It is also right to ask whether other measures could be taken to provide additional support. Yes, they can, which is why I have asked the NHS to review its own policies on the deployment of staff in certain settings, and that would include interaction with the most vulnerable patients.
(3 years ago)
Commons ChamberNo, I will not apologise for speeding up the booster programme to protect the health of the British public, and I will not apologise for asking the NHS to make it a priority. If the hon. Lady believes we should not be vaccinating people in this country, why does she not just say so?
It has been suggested more than once that, when deaths with covid are announced each day, it should simultaneously be stated how many of them were of unvaccinated people or of people with underlying health conditions or other specific vulnerabilities. Will the Secretary of State now undertake to do that? Did he notice, as I and no doubt others did, that the Prime Minister said this morning that one person in the UK had died with omicron, but the shadow Secretary of State said the death was a result of the virus. Does the Secretary of State know which version is correct?
My right hon. Friend is right to point to the distinction between, sadly, people who die with covid and those who die of covid. There is a difference. I have come to the Dispatch Box before to say, certainly with the delta variant—we do not have enough data on omicron yet for reasons that he will understand—that, as I am told by the NHS, approximately 20% of the people in hospital who have covid are there because they happen to have covid, rather than them being there because of covid.
(3 years ago)
Commons ChamberAs I said in response to a question earlier, whatever the rules—whether for this pandemic or anything else—they apply equally to everyone. With regard to Downing Street, as the Prime Minister has said today, there will be an investigation, and we should all await the outcome of that.
If bed capacity is the problem, were we right to close the Nightingale wards, and are they available for reopening? If so, does he expect to have to reopen them?
My right hon. Friend will not be surprised to hear that we will be taking measures to increase substantially capacity in the NHS. He will know that it is not just about beds, whether Nightingale or elsewhere, but having the right amount and type of workforce to help with those beds.
(3 years ago)
Commons ChamberYes, I can give the hon. Gentleman that assurance.
As someone who, very thankfully, received his booster jab last Thursday at the outstanding St Thomas’ Hospital, may I ask the Secretary of State why certain groups and communities seem to fear vaccination? Which are those groups and communities, and what can be done to persuade them that they are wrong?
There are many communities where vaccine take-up is lower than others. That has particularly been the case in the black African community in Britain and in some other black and minority ethnic communities—that has improved significantly over the past two to three months. The same is also the case in many other European countries and the US. A huge amount of work is being done through community leaders and communication campaigns, and by offering access to the vaccine in as many different ways as possible to encourage take-up.